Glycostem Therapeutics

Developer of allogeneic cellular immunotherapy for leukemia, lymphoma and solid tumors

placeOss, North Brabant, Netherlands calendar_todayFounded 2007 groups38 employees language glycostem.com

Innovation

6 patent families (3 granted) — focus: Chemistry & metallurgy, Human necessities; filing pace slowing. Cited 296 times.

YearFilings
20171
20181
20191
20203
20216
20223
20231
20251

Social engagement

Social engagement: 5.4K social following, 3 posts in the last 12 months — below the industry typical range.

Investor mix

6 investors on record.

Investor typeCountShare
Venture capital350%
Private equity117%
Other / undisclosed233%

Recent activity

23 Mar 2026
Recognition
Glycostem Therapeutics
Coming soon